Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice.
Costanzo A, Llamas-Velasco M, Fabbrocini G, Cuccia A, Rivera-Diaz R, Gaarn Du Jardin K, Kasujee I, Puig L, Carrascosa JM. Costanzo A, et al. Among authors: kasujee i. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2004-2015. doi: 10.1111/jdv.19229. Epub 2023 Jun 13. J Eur Acad Dermatol Venereol. 2023. PMID: 37246505
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study).
Augustin M, Sommer R, Daudén E, Laws P, de Jong E, Fabbrocini G, Naldi L, Navarini A, Lambert J, Reguiai Z, Gerdes S, Massana E, Obis T, Kasujee I, Mrowietz U. Augustin M, et al. Among authors: kasujee i. BMJ Open. 2023 Feb 15;13(2):e060536. doi: 10.1136/bmjopen-2021-060536. BMJ Open. 2023. PMID: 36792337 Free PMC article.
Implementing well-being in the management of psoriasis: An expert recommendation.
Sommer R, Mrowietz U, Gaarn Du Jardin K, Kasujee I, Martini E, Daudén E, Fabbrocini G, Zink A, Griffiths CEM, Augustin M. Sommer R, et al. Among authors: kasujee i. J Eur Acad Dermatol Venereol. 2024 Feb;38(2):302-310. doi: 10.1111/jdv.19567. Epub 2023 Oct 19. J Eur Acad Dermatol Venereol. 2024. PMID: 37822008 Review.
Application of the Statistical Method to Convert Published PASI 50/75/90/100 into Absolute PASI Response Rate in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab Based on Data from the Two Pivotal Phase 3 Studies reSURFACE 1 and reSURFACE 2.
Dykukha I, Schoenenberger A, Kasujee I, Mrowietz U, Vonthein R. Dykukha I, et al. Among authors: kasujee i. Dermatology. 2022;238(5):910-918. doi: 10.1159/000522009. Epub 2022 Feb 15. Dermatology. 2022. PMID: 35168231 Clinical Trial.
A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis.
Becher G, Conner S, Ingram JA, Stephen KE, McInnes AC, Heald AH, Riley PA, Davies M, Domenech A, Kasujee I. Becher G, et al. Among authors: kasujee i. Dermatol Ther (Heidelb). 2022 Oct;12(10):2343-2354. doi: 10.1007/s13555-022-00800-3. Epub 2022 Sep 9. Dermatol Ther (Heidelb). 2022. PMID: 36076145 Free PMC article.
Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
Bérard F, Ferrier Le Bouedec MC, Bouillet L, Reguiai Z, Barbaud A, Cambazard F, Milpied B, Pelvet B, Kasujee I, Gharbi H, Lacour JP. Bérard F, et al. Among authors: kasujee i. Br J Dermatol. 2019 Jan;180(1):56-66. doi: 10.1111/bjd.16904. Epub 2018 Sep 17. Br J Dermatol. 2019. PMID: 29927483 Clinical Trial.
Psychological impact on flare patterns and severity of atopic dermatitis.
Nielsen ML, Nymand LK, Pena AD, Du Jardin KG, Kasujee I, Thomsen SF, Egeberg A, Thein D. Nielsen ML, et al. Among authors: kasujee i. J Eur Acad Dermatol Venereol. 2024 Nov 12. doi: 10.1111/jdv.20427. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39530451 No abstract available.
Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panel.
Berman B, Armstrong A, Lebwohl M, Grada A, Bhatia N, Patel VA, Rigel D, Del Rosso J, Schlesinger T, Kircik L, Salem R, Narayanan S, Kasujee I. Berman B, et al. Among authors: kasujee i. JAAD Int. 2023 Sep 23;16:192-198. doi: 10.1016/j.jdin.2023.09.006. eCollection 2024 Sep. JAAD Int. 2023. PMID: 39040844 Free PMC article.
18 results